Chinook Gets Orphan Drug Designation from EC for Treatment of Primary IgA Nephropathy

  Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced the European Commission has granted orphan drug designation for BION-1301 for the treatment of primary IgA nephropathy (IgAN). The decision follows a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA).

https://www.biospace.com/article/releases/chinook-therapeutics-receives-orphan-drug-designation-from-european-commission-for-bion-1301-for-treatment-of-primary-iga-nephropathy-igan-/